Cargando…

Nanomedicine-based immunotherapy for central nervous system disorders

Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal diso...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanif, Sumaira, Muhammad, Pir, Chesworth, Rose, Rehman, Fawad Ur, Qian, Rong-jun, Zheng, Meng, Shi, Bing-yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468531/
https://www.ncbi.nlm.nih.gov/pubmed/32467570
http://dx.doi.org/10.1038/s41401-020-0429-z
_version_ 1783578239174705152
author Hanif, Sumaira
Muhammad, Pir
Chesworth, Rose
Rehman, Fawad Ur
Qian, Rong-jun
Zheng, Meng
Shi, Bing-yang
author_facet Hanif, Sumaira
Muhammad, Pir
Chesworth, Rose
Rehman, Fawad Ur
Qian, Rong-jun
Zheng, Meng
Shi, Bing-yang
author_sort Hanif, Sumaira
collection PubMed
description Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal disorders; however, their therapeutic success can be limited by the presence of the blood-brain barrier (BBB). Furthermore, unique immune functions within the CNS provide novel target mechanisms for the amelioration of CNS diseases. Recently, various therapeutic approaches have been applied to fight brain-related disorders, with moderate outcomes. Among the various therapeutic strategies, nanomedicine-based immunotherapeutic systems represent a new era that can deliver useful cargo with promising pharmacokinetics. These approaches exploit the molecular and cellular targeting of CNS disorders for enhanced safety, efficacy, and specificity. In this review, we focus on the efficacy of nanomedicines that utilize immunotherapy to combat CNS disorders. Furthermore, we detailed summarize nanomedicine-based pathways for CNS ailments that aim to deliver drugs across the BBB by mimicking innate immune actions. [Figure: see text]
format Online
Article
Text
id pubmed-7468531
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-74685312020-09-03 Nanomedicine-based immunotherapy for central nervous system disorders Hanif, Sumaira Muhammad, Pir Chesworth, Rose Rehman, Fawad Ur Qian, Rong-jun Zheng, Meng Shi, Bing-yang Acta Pharmacol Sin Review Article Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal disorders; however, their therapeutic success can be limited by the presence of the blood-brain barrier (BBB). Furthermore, unique immune functions within the CNS provide novel target mechanisms for the amelioration of CNS diseases. Recently, various therapeutic approaches have been applied to fight brain-related disorders, with moderate outcomes. Among the various therapeutic strategies, nanomedicine-based immunotherapeutic systems represent a new era that can deliver useful cargo with promising pharmacokinetics. These approaches exploit the molecular and cellular targeting of CNS disorders for enhanced safety, efficacy, and specificity. In this review, we focus on the efficacy of nanomedicines that utilize immunotherapy to combat CNS disorders. Furthermore, we detailed summarize nanomedicine-based pathways for CNS ailments that aim to deliver drugs across the BBB by mimicking innate immune actions. [Figure: see text] Springer Singapore 2020-05-28 2020-07 /pmc/articles/PMC7468531/ /pubmed/32467570 http://dx.doi.org/10.1038/s41401-020-0429-z Text en © CPS and SIMM 2020
spellingShingle Review Article
Hanif, Sumaira
Muhammad, Pir
Chesworth, Rose
Rehman, Fawad Ur
Qian, Rong-jun
Zheng, Meng
Shi, Bing-yang
Nanomedicine-based immunotherapy for central nervous system disorders
title Nanomedicine-based immunotherapy for central nervous system disorders
title_full Nanomedicine-based immunotherapy for central nervous system disorders
title_fullStr Nanomedicine-based immunotherapy for central nervous system disorders
title_full_unstemmed Nanomedicine-based immunotherapy for central nervous system disorders
title_short Nanomedicine-based immunotherapy for central nervous system disorders
title_sort nanomedicine-based immunotherapy for central nervous system disorders
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468531/
https://www.ncbi.nlm.nih.gov/pubmed/32467570
http://dx.doi.org/10.1038/s41401-020-0429-z
work_keys_str_mv AT hanifsumaira nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT muhammadpir nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT chesworthrose nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT rehmanfawadur nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT qianrongjun nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT zhengmeng nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders
AT shibingyang nanomedicinebasedimmunotherapyforcentralnervoussystemdisorders